Pipeline Moves: Pfizer scores in Phase II cancer cachexia trial
This week on Pipeline Moves, we kick off by looking at Pfizer’s topline data from a Phase II trial of…
Pipeline Moves
-
-
Pipeline Moves: Novo Nordisk’s liraglutide scores in Phase III paediatric trial
This week on Pipeline Moves, we kick off by looking at Novo Nordisk’s completion of a Phase III trial of…
-
Pipeline Moves: Investigator-led oncology cell therapy trial terminated
This week on Pipeline Moves, we kick off by looking at a Phase II termination of an investigator-led trial of…
-
Pipeline Moves: Moderna’s pandemic influenza vaccine trial completes
This week on Pipeline Moves, we kick off by looking at a Phase I/II trial completion by Moderna of its…
-
Pipeline Moves: Novartis terminates Phase II ALS trial after benefit-risk worry
This week on Pipeline Moves, we kick off by looking at a Phase II trial termination by Novartis after it…
-
Pipeline Moves: Novo Nordisk progression prospects drop after candidate terminated
This week on Pipeline Moves, we kick off by looking at Novo Nordisk’s acquired candidate belcesiran which the company has…
-
Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win
This week on Pipeline Moves, we start by looking at Alnylam’s Phase III win with Amvuttra in ATTR amyloidosis with…
-
Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
This week on Pipeline Moves, we kick off by looking at the completion of a Phase III trial of BioTissue's…
-
Pipeline Moves: Pfizer’s oral Nurtec approval prospects rise after Phase II/III completion
This week on Pipeline Moves, we kick off by looking at the completion of a Phase II/III trial of Pfizer’s…
-
Pipeline Moves: Phase III AML trial fails to meet primary endpoint
This week on Pipeline Moves, we kick off by looking at a Phase III trial of GlycoMimetics’ uproleselan sodium which…
